Healthcare >> Analyst Interviews >> May 13, 2003
MICHAEL LYTTON is Partner, Oxford Bioscience Partners. He joined Oxford
Bioscience Partners in 2001. Prior to that, he was Partner, Chairman of
the Technology Group and a member of the Executive Committee of Palmer &
Dodge LLP, a Boston-based law firm. Mr. Lytton serves on the Boards of
Directors of Acambis plc, ActivX Biosciences Inc., Descartes
Therapeutics, Inc., GPC Biotech AG, Graffinity Pharmaceutical Design
GmbH, Psychiatric Genomics Inc. and Rib-X Pharmaceuticals. Mr. Lytton is
also a member of the Research and Technology Development Committees of
the Beth Israel Deaconess Medical Center (an affiliated Harvard teaching
hospital) and the Center for Blood Research, Harvard Medical School,
where he is also a member of the Board of Overseers. In addition, he
serves on the Advisory Committee to Connecticut Innovations, a public
agency funding early-stage biomedical companies in Connecticut. Mr.
Lytton writes a column on issues facing early-stage biomedical companies
for Start-Up magazine, published by Windhover Information. Mr. Lytton
has served on the Executive Board of the MIT Enterprise Forum and the
Patent Committee of the Boston University Medical Center. Mr. Lytton was
a summa cum laude graduate of Princeton University and a recipient of a
Fulbright Scholarship for study at the University of London. Mr. Lytton
received a JD degree cum laude from Harvard Law School. Mr. Lytton also
received a MSc degree in Epidemiology and Medical Statistics from the
London School of Hygiene and Tropical Medicine. Profile
Partners?
Mr. Lytton: Oxford manages four funds with total assets of approximately
$900 million. We are an early stage
